Matthew Oliynik, Ms
About Matthew Oliynik, Ms
Matthew Oliynik is the Associate Director of Strategy & Operations Myeloid Brands, US Hematology at Bristol Myers Squibb in Summit, NJ.
Current Position at Bristol Myers Squibb
Matthew Oliynik currently serves as the Associate Director, Strategy & Operations Myeloid Brands in US Hematology at Bristol Myers Squibb. He has been with the company since September 2018, working out of Summit, NJ. In this role, he is part of the team that strategizes and oversees operations related to myeloid brands within the US hematology division.
Previous Role at Celgene
Before joining Bristol Myers Squibb, Matthew Oliynik worked at Celgene as a Senior Specialist in Global Regulatory Operations. He held this position from 2010 to 2018, accumulating eight years of experience. During his time at Celgene, he was responsible for various aspects of global regulatory operations, contributing significantly to the company’s regulatory affairs.
Work Experience at Eisai US
Matthew Oliynik worked at Eisai US as a Specialist in US Regulatory Operations for 11 months, from 2009 to 2010. During his tenure, he was involved in the regulatory processes within the US, helping to ensure compliance and facilitate the approval of drug products.
Employment at Bayer
In 2009, Matthew Oliynik spent 8 months at Bayer as a Specialist in Regulatory Operations within Global Regulatory Affairs. His role was based in Summit, NJ, where he was engaged in regulatory tasks at a global level, contributing to the company's strategic regulatory initiatives.
Educational Background
Matthew Oliynik holds an MS from Northeastern University, where he studied Regulatory Drug Development, Biologics, and Medical Devices. He also holds a BA in Communications from Susquehanna University. This diverse educational background has equipped him with the knowledge and skills necessary to navigate the complex regulatory landscape in the pharmaceutical industry.